SubHero Banner

Teva – Recall of losartan

April 29, 2019 - The FDA announced a voluntary, patient-level recall of Teva’s losartan tablets due to the detection of an impurity, N-Nitroso-N-methyl-4-aminobutyric acid (NMBA), found in six lots of active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited that is above the FDA’s interim acceptable exposure limit of 9.82 ppm.

Download PDF